Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: abuse-resistant analgesics - Acura Pharmaceuticals

Drug Profile

Research programme: abuse-resistant analgesics - Acura Pharmaceuticals

Alternative Names: acetaminophen/niacin/oxycodone; acetaminophen/oxycodone; acetaminophen/oxycodone/niacin; Acuracet; Acuracet with Niacin; niacin/acetaminophen/oxycodone; niacin/oxycodone/acetaminophen; niacin/oxycodone/paracetamol; niacin/paracetamol/oxycodone; oxycodone/acetaminophen; oxycodone/acetaminophen/niacin; oxycodone/niacin/acetaminophen; oxycodone/niacin/paracetamol; oxycodone/paracetamol; oxycodone/paracetamol/niacin; paracetamol/niacin/oxycodone; paracetamol/oxycodone; paracetamol/oxycodone/niacin

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acura Pharmaceuticals
  • Class Acetanilides; Morphine derivatives; Small molecules
  • Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (PO, Immediate release)
  • 26 Sep 2012 Acura Pharmaceuticals announced a letter agreement with Pfizer providing for the termination of Pfizer's license to Acura's AVERSION Technology used in three developmental opioid products as of 26 September 2012 and the transfer of those products, one of which is oxycodone/paracetamol and another undisclosed opioid, back to Acura. This represents an earlier return of development products to Acura
  • 26 Jul 2012 Pfizer exercises its right to terminate its licence for oxycodone/paracetamol and another undisclosed opioid in Canada, Mexico, USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top